Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL TOPICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL TOPICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 EPIDEMIOLOGY
2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL TOPICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES MODEL
4.3 COMPETITIVE INTELLIGENCE
5 INDUSTRY INSIGHTS
5.1 PATENT ANALYSIS
5.1.1 PATENT LANDSCAPE
5.1.2 USPTO NUMBER
5.1.3 PATENT EXPIRY
5.1.4 EPIO NUMBER
5.1.5 PATENT STRENGTH AND QUALITY
5.1.6 PATENT CLAIMS
5.1.7 PATENT CITATIONS
5.1.8 PATENT LITIGATION AND LICENSING
5.1.9 FILE OF PATENT
5.1.10 PATENT RECEIVED CONTRIES
5.1.11 TECHNOLOGY BACKGROUND
5.2 DRUG TREATMENT RATE BY MATURED MARKETS
5.3 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES
5.4 PATIENT FLOW DIAGRAM
5.5 KEY PRICING STRATEGIES
5.6 KEY PATIENT ENROLLMENT STRATEGIES
5.7 INTERVIEWS WITH SPECIALIST
5.8 OTHER KOL SNAPSHOTS
6 EPIDEMIOLOGY
6.1 INCIDENCE OF ALL BY GENDER
6.2 TREATMENT RATE
6.3 MORTALITY RATE
6.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL
6.5 PATIENT TREATMENT SUCCESS RATES
7 MERGERS AND ACQUISITION
7.1 LICENSING
7.2 COMMERCIALIZATION AGREEMENTS
8 REGULATORY FRAMEWORK
8.1 REGULATORY APPROVAL PROCESS
8.2 GEOGRAPHIES’ EASE OF REGULATORY APPROVAL
8.3 REGULATORY APPROVAL PATHWAYS
8.4 LICENSING AND REGISTRATION
8.5 POST-MARKETING SURVEILLANCE
8.6 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES
9 PIPELINE ANALYSIS
9.1 CLINICAL TRIALS AND PHASE ANALYSIS
9.2 DRUG THERAPY PIPELINE
9.3 PHASE III CANDIDATES
9.4 PHASE II CANDIDATES
9.5 PHASE I CANDIDATES
9.6 OTHERS (PRE-CLINICAL AND RESEARCH)
TABLE 1 GLOBAL TOPICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET
Company Name Therapeutic Area
XX XX
XX XX
XX XX
XX XX
XX XX
XX XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
TABLE 2 DISTRIBUTION OF PRODUCTS AND PROJECTS BY PHASE TOPICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET
Phase Number of Projects
Preclinical/Research Projects XX
Clinical Development XX
Phase I XX
Phase II XX
Phase III XX
U.S. Filed/Approved But Not Yest Marketed XX
Total XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
TABLE 3 DISTRIBUTION OF PROJECTS BY THERAPEUTIC AREA AND PHASE TOPICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET
Therapeutic Area Preclinical/ Research Project
XX XX
XX XX
XX XX
XX XX
XX XX
Total Projects XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
TABLE 4 DISTRIBUTION OF PROJECTS BY SCIENTIFIC APPROACH AND PHASE TOPICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET
Technology Preclinical/ Research Project
XX XX
XX XX
XX XX
XX XX
XX XX
Total Projects XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
FIGURE 1 TOP ENTITIES BASED ON R&D GLANCE FOR TOPICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
10 MARKETED DRUG ANALYSIS
10.1 DRUG
10.1.1 BRAND NAME
10.1.2 GENERICS NAME
10.2 THERAPEUTIC INDIACTION
10.3 PHARACOLOGICAL CLASS OD THE DRUG
10.4 DRUG PRIMARY INDICATION
10.5 MARKET STATUS
10.6 MEDICATION TYPE
10.7 DRUG DOSAGES FORM
10.8 DOSAGES AVAILABILITY
10.9 PACKAGING TYPE
10.1 DRUG ROUTE OF ADMINISTRATION
10.11 DOSING FREQUENCY
10.12 DRUG INSIGHT
10.13 AN OVERVIEW OF THE DRUG DEVELOPMENT ACTIVITIES SUCH AS REGULATORY MILSTONE, SAFETY DATA AND EFFICACY DATA, MARKET EXCLUSIVITY DATA.
10.13.1 FORECAST MARKET OUTLOOK
10.13.2 CROSS COMPETITION
10.13.3 THERAPEUTIC PORTFOLIO
10.13.4 CURRENT DEVELOPMENT SCENARIO
11 MARKET ACCESS
11.1 10-YEAR MARKET FORECAST
11.2 CLINICAL TRIAL RECENT UPDATES
11.3 ANNUAL NEW FDA APPROVED DRUGS
11.4 DRUGS MANUFACTURER AND DEALS
11.5 MAJOR DRUG UPTAKE
11.6 CURRENT TREATMENT PRACTICES
11.7 IMPACT OF UPCOMING THERAPY
12 R & D ANALYSIS
12.1 COMPARATIVE ANALYSIS
12.2 DRUG DEVELOPMENTAL LANDSCAPE
12.3 IN-DEPTH INSIGHTS ON REGULATORY MILESTONES
12.4 THERAPEUTIC ASSESSMENT
12.5 ASSET-BASED COLLABORATIONS AND PARTNERSHIPS
13 MARKET OVERVIEW
13.1 DRIVERS
13.2 RESTRAINTS
13.3 OPPORTUNITIES
13.4 CHALLENGES
14 GLOBAL TOPICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET, BY TYPE
14.1 OVERVIELW
14.2 NON-SELECTIVE NSAIDS
14.2.1 BY DRUG TYPE
14.2.1.1. ACETYLATED SALICYLATES (ASPIRIN)
14.2.1.1.1. NON-ACETYLATED SALICYLATES
14.2.1.1.1.1 DIFLUNISAL
14.2.1.1.1.2 SALSALATE
14.2.1.1.1.3 OTHERS
14.2.1.1.2. PROPIONIC ACIDS
14.2.1.1.2.1 NAPROXEN
14.2.1.1.2.2 IBUPROFEN
14.2.1.1.2.3 FLURBIPROFEN
14.2.1.1.2.4 KETOPROFEN
14.2.1.1.2.5 OTHERS
14.2.1.1.3. ACETIC ACIDS
14.2.1.1.3.1 DICLOFENAC
14.2.1.1.3.2 INDOMETHACIN
14.2.1.1.3.3 OTHERS
14.2.1.1.4. ENOLIC ACID
14.2.1.1.4.1 PIROXICAM
14.2.1.1.4.2 OTHERS
14.2.1.1.5. BUFEXAMIC ACID
14.2.1.1.6. CELEBREX
14.2.1.1.7. KETOROLAC TROMETHAMINE
14.2.1.1.8. ETODOLAC
14.2.1.1.9. OTHERS
14.2.2 INDICATION
14.2.2.1. ARTHRITIS
14.2.2.1.1. DRUG TYPE
14.2.2.1.1.1 ACETYLATED SALICYLATES(ASPRIN)
14.2.2.1.1.2 NON-ACETYLATED SALICYLATES
14.2.2.1.1.3 PROPIONIC ACIDS
14.2.2.1.1.4 ACETIC ACIDS
14.2.2.1.1.5 ENOLIC ACIDS
14.2.2.1.1.6 BUFEXAMIC ACID
14.2.2.1.1.7 OTHERS
14.3 COMBINATION PRODUCTS
14.3.1 INDICATION
14.3.1.1. OSTEOARTHRITIS
14.3.1.1.1.1 BY DRUG TYPE
14.3.1.1.1.1.1. ACETYLATED SALICYLATES(ASPRIN)
14.3.1.1.1.1.2. NON-ACETYLATED SALICYLATES
14.3.1.1.1.1.3. PROPIONIC ACIDS
14.3.1.1.1.1.4. ACETIC ACIDS
14.3.1.1.1.1.5. ENOLIC ACIDS
14.3.1.1.1.1.6. BUFEXAMIC ACID
14.3.1.1.1.1.7. CELEBREX
14.3.1.1.1.1.8. CELECOXIB CAPSULES
14.3.1.1.1.1.9. OTHERS
14.3.1.2. MIGRAINE
14.3.1.3. ECZEMA
14.3.1.4. OPHTHALMIC DISEASES (BROMSITE)
14.3.1.5. KERATOSIS
14.3.1.6. MUSCLE PAIN (NAPROXEN EC)
14.3.1.7. OTHERS
15 GLOBAL TOPICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET, BY DRUG TYPE
15.1 OVERVIEW
15.2 GENERIC
15.3 BRANDED
15.3.1 VOLTAREN
15.3.2 FLECTOR
15.3.3 PENNSAID
15.3.4 SOLARAZE
15.3.5 ZICLOPRO
15.3.6 OTHERS
16 GLOBAL TOPICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET, BY MODE OF PURCHASE
16.1 OVERVIEW
16.2 OVER THE COUNTER
16.3 PRESCRIPTION
17 GLOBAL TOPICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET, BY AGE GROUP
17.1 OVERVIEW
17.2 PEDIATRIC
17.3 ADULT
17.4 ELDER
18 GLOBAL TOPICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET, BY DOSES FORM
18.1 OVERVIEW
18.2 CREAMS
18.3 GEL
18.4 OINTMENT
18.5 SPRAY
18.6 RUBS
18.7 SOLUTION
18.8 OTHERS
19 GLOBAL TOPICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET, BY END USER
19.1 OVERVIEW
19.2 HOSPITALS
19.3 CLINICS
19.4 HOME HEALTHCARE
19.5 SPECIALITY CENTER
19.6 AMBULTORY CENTERS
19.7 OTHERS
20 GLOBAL TOPICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET, BY DISTRIBUTION CHANNEL
20.1 OVERVIEW
20.2 DIRECT TENDER
20.3 HOSPITAL PHARMACY
20.4 RETAIL PHARMACY SALES
20.4.1 OFFLINE SALES
20.4.1.1. HOSPITAL PHARMACY
20.4.1.2. RETAIL PHARMACY
20.4.1.3. OTHERS
20.4.2 ONLINE SALES
20.4.2.1. E-STORES
20.4.2.2. COMPANY WEBSITE
20.4.2.3. OTHERS
20.5 OTHERS
21 GLOBAL TOPICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET, COMPANY LANDSCAPE
21.1 COMPANY SHARE ANALYSIS: GLOBAL
21.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
21.3 COMPANY SHARE ANALYSIS: EUROPE
21.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
21.5 MERGERS & ACQUISITIONS
21.6 NEW PRODUCT DEVELOPMENT & APPROVALS
21.7 EXPANSIONS
21.8 REGULATORY CHANGES
21.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
22 GLOBAL TOPICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET, BY GEOGRAPHY
22.1 GLOBAL TOPICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
22.1.1 NORTH AMERICA
22.1.1.1. U.S.
22.1.1.1.1. U.S. TOPICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET, BY TYPE
22.1.1.1.2. U.S. TOPICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET, BY DRUG TYPE
22.1.1.1.3. U.S. TOPICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET, BY MODE OF PURCHASE
22.1.1.1.4. U.S. TOPICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET, BY AGE GROUP
22.1.1.1.5. U.S. TOPICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET, BY DOSES FORM
22.1.1.1.6. U.S. TOPICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET, BY END USER
22.1.1.1.7. U.S. TOPICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET, BY DISTRIBUTION CHANNEL
22.1.2 CANADA
22.1.3 MEXICO
22.2 EUROPE
22.2.1 GERMANY
22.2.2 FRANCE
22.2.3 U.K.
22.2.4 ITALY
22.2.5 SPAIN
22.2.6 RUSSIA
22.2.7 TURKEY
22.2.8 NETHERLANDS
22.2.9 SWITZERLAND
22.2.10 AUSTRIA
22.2.11 IRELAND
22.2.12 NORWAY
22.2.13 POLAND
22.2.14 REST OF EUROPE
22.3 ASIA-PACIFIC
22.3.1 JAPAN
22.3.2 CHINA
22.3.3 TAIWAN
22.3.4 SOUTH KOREA
22.3.5 INDIA
22.3.6 AUSTRALIA
22.3.7 SINGAPORE
22.3.8 THAILAND
22.3.9 MALAYSIA
22.3.10 INDONESIA
22.3.11 PHILIPPINES
22.3.12 VIETNAM
22.3.13 REST OF ASIA-PACIFIC
22.4 SOUTH AMERICA
22.4.1 BRAZIL
22.4.2 ARGENTINA
22.4.3 CHILE
22.4.4 PERU
22.4.5 REST OF SOUTH AMERICA
22.5 MIDDLE EAST AND AFRICA
22.5.1 SOUTH AFRICA
22.5.2 SAUDI ARABIA
22.5.3 UAE
22.5.4 EGYPT
22.5.5 KUWAIT
22.5.6 ISRAEL
22.5.7 REST OF MIDDLE EAST AND AFRICA
22.6 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
23 GLOBAL TOPICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET, SWOT AND DBMR ANALYSIS
24 GLOBAL TOPICAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET, COMPANY PROFILE
24.1 F. HOFFMANN-LA ROCHE LTD.
24.1.1 COMPANY OVERVIEW
24.1.2 REVENUE ANALYSIS
24.1.3 GEOGRAPHIC PRESENCE
24.1.4 PRODUCT PORTFOLIO
24.1.5 RECENT DEVELOPMENTS
24.2 IBSA PHARMA INC
24.2.1 COMPANY OVERVIEW
24.2.2 REVENUE ANALYSIS
24.2.3 GEOGRAPHIC PRESENCE
24.2.4 PRODUCT PORTFOLIO
24.2.5 RECENT DEVELOPMENTS
24.3 UNIPRIX
24.3.1 COMPANY OVERVIEW
24.3.2 REVENUE ANALYSIS
24.3.3 GEOGRAPHIC PRESENCE
24.3.4 PRODUCT PORTFOLIO
24.3.5 RECENT DEVELOPMENTS
24.4 AMGEN INC
24.4.1 COMPANY OVERVIEW
24.4.2 REVENUE ANALYSIS
24.4.3 GEOGRAPHIC PRESENCE
24.4.4 PRODUCT PORTFOLIO
24.4.5 RECENT DEVELOPMENTS
24.5 PFIZER INC.
24.5.1 COMPANY OVERVIEW
24.5.2 REVENUE ANALYSIS
24.5.3 GEOGRAPHIC PRESENCE
24.5.4 PRODUCT PORTFOLIO
24.5.5 RECENT DEVELOPMENTS
24.6 LUPIN
24.6.1 COMPANY OVERVIEW
24.6.2 REVENUE ANALYSIS
24.6.3 GEOGRAPHIC PRESENCE
24.6.4 PRODUCT PORTFOLIO
24.6.5 RECENT DEVELOPMENTS
24.7 MAYNE PHARMA GROUP LIMITED
24.7.1 COMPANY OVERVIEW
24.7.2 REVENUE ANALYSIS
24.7.3 GEOGRAPHIC PRESENCE
24.7.4 PRODUCT PORTFOLIO
24.7.5 RECENT DEVELOPMENTS
24.8 NOVARTIS
24.8.1 COMPANY OVERVIEW
24.8.2 REVENUE ANALYSIS
24.8.3 GEOGRAPHIC PRESENCE
24.8.4 PRODUCT PORTFOLIO
24.8.5 RECENT DEVELOPMENTS
24.9 TEVA PHARMACEUTICAL INDUSTRIES LTD.
24.9.1 COMPANY OVERVIEW
24.9.2 REVENUE ANALYSIS
24.9.3 GEOGRAPHIC PRESENCE
24.9.4 PRODUCT PORTFOLIO
24.9.5 RECENT DEVELOPMENTS
24.1 SUN PHARMACEUTICAL INDUSTRIES LTD.
24.10.1 COMPANY OVERVIEW
24.10.2 REVENUE ANALYSIS
24.10.3 GEOGRAPHIC PRESENCE
24.10.4 PRODUCT PORTFOLIO
24.10.5 RECENT DEVELOPMENTS
24.11 CIPLA INC.
24.11.1 COMPANY OVERVIEW
24.11.2 REVENUE ANALYSIS
24.11.3 GEOGRAPHIC PRESENCE
24.11.4 PRODUCT PORTFOLIO
24.11.5 RECENT DEVELOPMENTS
24.12 GLENMARK PHARMACEUTICALS U.S. INC., USA
24.12.1 COMPANY OVERVIEW
24.12.2 REVENUE ANALYSIS
24.12.3 GEOGRAPHIC PRESENCE
24.12.4 PRODUCT PORTFOLIO
24.12.5 RECENT DEVELOPMENTS
24.13 JOHNSON & JOHNSON CONSUMER INC.
24.13.1 COMPANY OVERVIEW
24.13.2 REVENUE ANALYSIS
24.13.3 GEOGRAPHIC PRESENCE
24.13.4 PRODUCT PORTFOLIO
24.13.5 RECENT DEVELOPMENTS
24.14 APOTEX INC.
24.14.1 COMPANY OVERVIEW
24.14.2 REVENUE ANALYSIS
24.14.3 GEOGRAPHIC PRESENCE
24.14.4 PRODUCT PORTFOLIO
24.14.5 RECENT DEVELOPMENTS
24.15 RECKITT BENCKISER GROUP PLC
24.15.1 COMPANY OVERVIEW
24.15.2 REVENUE ANALYSIS
24.15.3 GEOGRAPHIC PRESENCE
24.15.4 PRODUCT PORTFOLIO
24.15.5 RECENT DEVELOPMENTS
24.16 BAYER AG
24.16.1 COMPANY OVERVIEW
24.16.2 REVENUE ANALYSIS
24.16.3 GEOGRAPHIC PRESENCE
24.16.4 PRODUCT PORTFOLIO
24.16.5 RECENT DEVELOPMENTS
24.17 TORRENT PHARMACEUTICALS LTD.
24.17.1 COMPANY OVERVIEW
24.17.2 REVENUE ANALYSIS
24.17.3 GEOGRAPHIC PRESENCE
24.17.4 PRODUCT PORTFOLIO
24.17.5 RECENT DEVELOPMENTS
24.18 ADVACARE PHARMA
24.18.1 COMPANY OVERVIEW
24.18.2 REVENUE ANALYSIS
24.18.3 GEOGRAPHIC PRESENCE
24.18.4 PRODUCT PORTFOLIO
24.18.5 RECENT DEVELOPMENTS
24.19 INTAS PHARMACEUTICALS LTD.
24.19.1 COMPANY OVERVIEW
24.19.2 REVENUE ANALYSIS
24.19.3 GEOGRAPHIC PRESENCE
24.19.4 PRODUCT PORTFOLIO
24.19.5 RECENT DEVELOPMENTS
24.2 AMNEAL PHARMACEUTICALS
24.20.1 COMPANY OVERVIEW
24.20.2 REVENUE ANALYSIS
24.20.3 GEOGRAPHIC PRESENCE
24.20.4 PRODUCT PORTFOLIO
24.20.5 RECENT DEVELOPMENTS
24.21 DAIICHI SANKYO COMPANY, LIMITED
24.21.1 COMPANY OVERVIEW
24.21.2 REVENUE ANALYSIS
24.21.3 GEOGRAPHIC PRESENCE
24.21.4 PRODUCT PORTFOLIO
24.21.5 RECENT DEVELOPMENTS
24.22 GEBRO PHARMA GMBH
24.22.1 COMPANY OVERVIEW
24.22.2 REVENUE ANALYSIS
24.22.3 GEOGRAPHIC PRESENCE
24.22.4 PRODUCT PORTFOLIO
24.22.5 RECENT DEVELOPMENTS
24.23 INCEPTA PHARMACEUTICALS LTD.
24.23.1 COMPANY OVERVIEW
24.23.2 REVENUE ANALYSIS
24.23.3 GEOGRAPHIC PRESENCE
24.23.4 PRODUCT PORTFOLIO
24.23.5 RECENT DEVELOPMENTS
NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST
25 RELATED REPORTS
26 CONCLUSION
27 QUESTIONNAIRE
28 ABOUT DATA BRIDGE MARKET RESEARCH
